Clinical Trial Update: Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of a quadrivalent HPV vaccine (types 6, 11, 16, 18) labeled V501-007 was completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections, Genital Diseases, Female | Phase 2 | Status: COMPLETED | Results posted: 2010-08-03